NCT00800267

A Study of Glaucoma or Ocular Hypertension in Patients Within the United States

A 6-month, Randomized, Double-masked Comparison of Fixed Combination of Latanoprost and Timolol With the Individual Components, Continuing Into a 6-month Open Label Safety Study of Fixed Combination in Patients With Glaucoma or Ocular Hypertension. A Multicenter Study in the United States

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 418 (actual)
• Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Safety and efficacy study comparing between fixed combination latanoprost-timolol and its component parts.

Conditions

• Ocular Hypertension
• Glaucoma

Interventions

Type	Name	Description
DRUG	latanoprost 0.005%	placebo in the morning and latanoprost .005% in the evening
DRUG	fixed combination latanoprost-timolol	one drop in the morning and placebo in the evening
DRUG	timolol 0.5%	one drop in the morning and evening

Timeline

• Start date: 1997-07-01
• Primary completion: 1999-06-01
• Completion: 1999-06-01
• First posted: 2008-12-02
• Last updated: 2021-02-18

Locations

53 sites across 1 country: United States